Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes.
A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.
As Director Regulatory Affairs you will be responsible for developing and executing global regulatory strategies to support the submission, approval and market launch of the company´s biologics. Since the organization is in a development phase, there are great opportunities to contribute during a very exciting and expansive period. The office is based in Stockholm City and you will report to the Chief Operating Officer at Diamyd Medical. Hybrid working solution is possible.
Key Responsibilities:
Qualifications:
Welcome to apply via haegercarlsson.com Questions are answered by:
Lena Sörskog +46 (0)70-692 45 70, lena@haegercarlsson.com
Anna Freese +46 (0)76-174 75 81, anna.f@haegercarlsson.com
Apply